TY - JOUR
T1 - The role of glutamate in mood disorders
T2 - Results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects
AU - Maeng, Sungho
AU - Zarate, Carlos A.
N1 - Funding Information:
This study was supported by the Intramural Research Program at the National Institute of Mental Health, National Institutes of Health, and Department of Health and Human Services. Dr. Zarate is listed among the inventors on a patent application submitted for the use of ketamine in treating depression. He has assigned his rights on the patent to the US government.
PY - 2007/12
Y1 - 2007/12
N2 - In this article, we first review a study showing that the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine leads to rapid, robust, and relatively sustained antidepressant effects in patients with treatment-resistant major depression. We then discuss our hypothesis that the therapeutic effects of monoaminergic antidepressants and ketamine may be mediated by increased AMPA-to-NMDA glutamate receptor throughput in critical neuronal circuits. We hypothesize that ketamine directly mediates this throughput, whereas monoaminergic antidepressants work indirectly and gradually; this may explain, in part, the lag of onset of several weeks to months that is observed with traditional antidepressants.
AB - In this article, we first review a study showing that the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine leads to rapid, robust, and relatively sustained antidepressant effects in patients with treatment-resistant major depression. We then discuss our hypothesis that the therapeutic effects of monoaminergic antidepressants and ketamine may be mediated by increased AMPA-to-NMDA glutamate receptor throughput in critical neuronal circuits. We hypothesize that ketamine directly mediates this throughput, whereas monoaminergic antidepressants work indirectly and gradually; this may explain, in part, the lag of onset of several weeks to months that is observed with traditional antidepressants.
UR - http://www.scopus.com/inward/record.url?scp=37349049304&partnerID=8YFLogxK
U2 - 10.1007/s11920-007-0063-1
DO - 10.1007/s11920-007-0063-1
M3 - Review article
C2 - 18221626
AN - SCOPUS:37349049304
VL - 9
SP - 467
EP - 474
JO - Current Psychiatry Reports
JF - Current Psychiatry Reports
SN - 1523-3812
IS - 6
ER -
